Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

28.35USD
8 Dec 2017
Change (% chg)

$0.30 (+1.07%)
Prev Close
$28.05
Open
$28.25
Day's High
$29.15
Day's Low
$28.10
Volume
137,833
Avg. Vol
156,816
52-wk High
$30.10
52-wk Low
$14.95

Chart for

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.83
Market Cap(Mil.): $1,067.87
Shares Outstanding(Mil.): 37.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

Dec 01 2017

BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL

* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®

Nov 29 2017

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

Nov 06 2017

BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​

* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​ Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:

Nov 06 2017

BRIEF-Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"

* Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​

Nov 01 2017

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

Oct 30 2017

BRIEF-Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC

* Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC

Oct 02 2017

BRIEF-Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

* Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

Sep 27 2017

BRIEF-Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

* Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

Sep 26 2017

BRIEF-Lannett announces dismissal of class action lawsuit

* Lannett Company - judge dismissed in entirety putative class action lawsuit against a multitude of generic drug manufacturers including Lannett​ Source text for Eikon: Further company coverage:

Sep 26 2017

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $95.95 +1.71
Pfizer Limited (PFIZ.NS) Rs1,949.80 +40.45
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,185.45 -10.90

Earnings vs. Estimates